More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$221951670
EPS
-2.34
P/E ratio
--
Price to sales
15.78
Dividend yield
--
Beta
1.132047
Previous close
$10.03
Today's open
$10.02
Day's range
$10.02 - $11.80
52 week range
$8.98 - $22.55
show more
CEO
Jasbir Seehra
Employees
92
Headquarters
Lexington, MA
Exchange
NASDAQ Global Market
Shares outstanding
19624374
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization
LEXINGTON, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a new $5 million share repurchase program of the Company's common stock following receipt of a $20 million development milestone payment under the license agreement of elritercept with Takeda Pharmaceuticals U.S.A., Inc., following the dosing of the first patient in the ELRiSE MF clinical trial. This approval grants Keros' management the authority to repurchase outstanding shares of the Company's common stock, from time to time, in the open market and/or by such other means in accordance with applicable state and federal securities laws.
GlobeNewsWire • Nov 16, 2026

New Strong Buy Stocks for November 12th
PANL, CBRL, KROS, NEPH and LRN have been added to the Zacks Rank #1 (Strong Buy) List on November 12, 2026.
Zacks Investment Research • Nov 12, 2026

Down 21% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround
Keros Therapeutics (KROS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks Investment Research • Nov 10, 2026

Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates
Keros Therapeutics, Inc. (KROS) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of a loss of $0.96 per share. This compares to a loss of $0.18 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
Keros Therapeutics NASDAQ: KROS is repositioning its pipeline around rinvatercept, a skeletal-muscle regeneration candidate being developed for neuromuscular diseases, while its partnered program eleriscept advances through late-stage development under Takeda, Chief Executive Officer Jasbir Seehra said during a fireside chat hosted by Chardan.
MarketBeat • Oct 22, 2026

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis (“MF”) and anemia on concurrent ruxolitinib therapy.
GlobeNewsWire • Sep 29, 2026

KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
Zacks Investment Research • Sep 29, 2026

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy (“DMD”).
GlobeNewsWire • Sep 28, 2026

Keros Therapeutics Announces $5 Million Share Repurchase Authorization
LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a $5 million share repurchase program of the Company's common stock following receipt of a $20 million development milestone payment under the license agreement of elritercept with Takeda Pharmaceuticals U.S.A., Inc., following the dosing of the first patient in the ELRiSE MDS clinical trial. This approval grants Keros' management the authority to repurchase outstanding shares of the Company's common stock, from time to time, in the open market and/or by such other means in accordance with applicable state and federal securities laws.
GlobeNewsWire • Sep 8, 2026

Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research • Sep 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Keros Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.